HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) reported new real-world evidence showing that patients with metastatic castration-sensitive prostate cancer who began treatment with ERLEADA without ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results